Presynaptic effects of levodopa and their possible role in dyskinesia. - Wikidata - awgldk - TriplyDB

Presynaptic effects of levodopa and their possible role in dyskinesia.

Presynaptic effects of levodopa and their possible role in dyskinesia.

http://www.wikidata.org/entity/Q35040280

about

Striatal dopamine neurotransmission: regulation of release and uptake Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.Dysregulation of striatal projection neurons in Parkinson's disease.Dissociation of metabolic and hemodynamic levodopa responses in the 6-hydroxydopamine rat model.Unmasking the Effects of L-DOPA on Rapid Dopamine Signaling with an Improved Approach for Nafion Coating Carbon-Fiber Microelectrodes.Vesicular Monoamine Transporter 2 (VMAT2) Level Regulates MPTP Vulnerability and Clearance of Excess Dopamine in Mouse Striatal Terminals.Levodopa: 50 years of a revolutionary drug for Parkinson disease.Synaptic plasticity may underlie l-DOPA induced dyskinesia.The abnormal activation of D1R/Shp-2 complex involved in levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's rats

P2860

Q34524803-881DEB8E-43FE-49BD-8DE9-7AAB02E3F057 Q36744366-B00603BB-7471-46E7-B146-3D8EECAE87B5 Q38722989-7812FDB7-A483-4278-976C-AA9730BDF61F Q39470500-678E7AB9-1AED-4149-8BB2-B3938174B4D8 Q39577328-A089725C-30BF-4EC6-868F-78A0CB7EC92D Q41031814-85ED3C18-C82B-4E79-B9D2-B9034B468C5E Q48056860-3BBD19B2-8A82-44A8-8861-B44B24F17DBD Q50069510-28743EED-F9CA-4C84-93BF-75ED3C9A7FA5 Q57177116-B8DF51B9-AD1C-44D3-965E-2BB07E33F590

P2860

Presynaptic effects of levodopa and their possible role in dyskinesia.

http://www.wikidata.org/entity/Q35040280

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Presynaptic effects of levodopa and their possible role in dyskinesia.

@ast

Presynaptic effects of levodopa and their possible role in dyskinesia.

@en

type

label

Presynaptic effects of levodopa and their possible role in dyskinesia.

@ast

Presynaptic effects of levodopa and their possible role in dyskinesia.

@en

prefLabel

Presynaptic effects of levodopa and their possible role in dyskinesia.

@ast

Presynaptic effects of levodopa and their possible role in dyskinesia.

@en

P1433

Q35040280-F6461B69-425B-4A28-A5B1-0B813BB8039F

P1476

Q35040280-7260F043-D727-42B4-A7EC-F46BE865107A

P2093

Q35040280-41BF0ECC-E71D-4D46-9B67-7F390D0E72EA

Q35040280-BABD9052-6C8D-414B-A067-9EAC5D80AB19

P2860

Q35040280-007C0444-4BE5-4487-9BAE-E46536285CE4

Q35040280-03A0D10A-A39F-44A4-B98A-4C5951B0BE5E

Q35040280-068AD474-7FB4-4814-9297-8B18F5E99AD3

Q35040280-0D2CA974-6BD1-4E2D-B565-BECD6CD6FC39

Q35040280-0F288A27-5D6B-449F-B349-33C5C70BC7AC

Q35040280-100A6E89-997A-4FEE-81B7-E1740203E44E

Q35040280-119F642C-C801-4A03-92F1-B7BBBD903624

Q35040280-1998154B-8B30-4F38-AD95-A82F97A466E0

Q35040280-1A1CF01F-423E-4B03-8A96-2262CC07671A

Q35040280-1DFF1F57-BB6F-4869-B79B-7244DB141DA0

P304

Q35040280-5BBC2765-BE0E-41E4-A111-61BD128BE9AC

P31

Q35040280-AB6AD7D3-0DF0-44B7-B514-E614C816F2A5

P356

Q35040280-45224FD6-FA22-4B4E-8C75-85018FC0F33E

P407

Q35040280-47684245-D402-48BD-835B-C5DB7545B5B8

P433

Q35040280-C09725EF-0224-4EC7-931C-9250EF3162E3

P478

Q35040280-F6F15B03-5D44-4013-9C57-797AA65A7BFE

P50

Q35040280-A4E01A6A-1FE1-4FC2-94BF-E60E4BCC3AE3

P577

Q35040280-630E6754-76F8-469E-892D-3B9E19191A68

P5875

Q35040280-038241B6-E83F-43F7-BBE2-559361F76E25

P698

Q35040280-E9480809-1927-4F47-B329-DB206112C603

P921

Q35040280-2148C546-B677-4F11-A5B1-E9B5B7EE1928

Q35040280-785A7643-585E-4684-A196-AF82F63E48D9

P932

Q35040280-9DEB0071-2187-4DE6-8C45-BAB6398BBDFA

P356

P1433

Movement Disorders

P1476

Presynaptic effects of levodopa and their possible role in dyskinesia.

@en

P2093

Anders Borgkvist

http://www.w3.org/2001/XMLSchema#string

Eugene V Mosharov

http://www.w3.org/2001/XMLSchema#string

P2860

Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter

Temporally resolved catecholamine spikes correspond to single vesicle release from individual chromaffin cells

Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry

How addictive drugs disrupt presynaptic dopamine neurotransmission

Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders

Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration

Profound neuronal plasticity in response to inactivation of the dopamine transporter

Altered dopamine release and uptake kinetics in mice lacking D2 receptors

Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study

Localization and functional significance of striatal neurons immunoreactive to aromatic L-amino acid decarboxylase or tyrosine hydroxylase in rat Parkinsonian models.

P304

45-53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.26103

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

268988857

http://www.w3.org/2001/XMLSchema#string

P698

25450307

http://www.w3.org/2001/XMLSchema#string

P921

P932

4314471

http://www.w3.org/2001/XMLSchema#string